This phase II trial studies how well whole brain radiation therapy works with standard
temozolomide chemo-radiotherapy and plerixafor in treating patients with glioblastoma (brain
tumor). Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.
Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth
of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. Plerixafor is a drug that may prevent recurrence of glioblastoma after
radiation treatment. Giving whole brain radiation therapy with standard temozolomide
chemo-radiotherapy and plerixafor may work better in treating patients with glioblastoma.
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Stanford Cancer Institute Palo Alto, Palo Alto, California
Stanford Cancer Institute Palo Alto
Palo Alto, California, 94304